ARS Pharmaceuticals Inc.

09/08/2024 | Press release | Distributed by Public on 09/08/2024 17:08

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.